No Impact of Fluconazole to Echinocandins Replacement as First-Line Therapy on the Epidemiology of Yeast Fungemia (Hospital-Driven Active Surveillance, 2004-2017, Paris, France).

candidemia echinocandins epidemiology fluconazole fungemia hematological malignancy intensive care unit solid cancer

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2021
Historique:
received: 15 12 2020
accepted: 15 03 2021
entrez: 7 5 2021
pubmed: 8 5 2021
medline: 8 5 2021
Statut: epublish

Résumé

Replacement of fluconazole by echinocandins as the first-line therapy for yeast-related fungemia could have an impact on both the mortality rate and the epidemiology of yeast species responsible for candidemia. We analyzed the individual clinical and microbiological data collected through the active surveillance program on yeast fungemia (YEASTS program, 2004-2016, Paris area, France) within 14 University Hospitals. The cohort included 3,092 patients [male:female ratio: 1.56; median age 61.0 years (IQR: 23.8)]. The mean mortality rate within 30 days was 38.5% (1,103/2,868) and significantly higher in intensive care units (690/1,358, 50.8%) than outside (413/1,510, 27.4%,

Identifiants

pubmed: 33959624
doi: 10.3389/fmed.2021.641965
pmc: PMC8093410
doi:

Types de publication

Journal Article

Langues

eng

Pagination

641965

Informations de copyright

Copyright © 2021 Bretagne, Desnos-Ollivier, Sitbon, Lortholary, Che, Dromer and Participants of the YEASTS.

Déclaration de conflit d'intérêts

SB has received travel grant from Pfizer in 2018 and has served on scientific advisory board for Gilead until 2018. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

N Engl J Med. 2018 Oct 4;379(14):1322-1331
pubmed: 30281988
Clin Microbiol Infect. 2013 Aug;19(8):E343-53
pubmed: 23607326
Clin Infect Dis. 2012 Apr;54(8):1110-22
pubmed: 22412055
Crit Care. 2020 Mar 18;24(1):109
pubmed: 32188500
Braz J Infect Dis. 2013 May-Jun;17(3):283-312
pubmed: 23693017
Antimicrob Agents Chemother. 2008 Sep;52(9):3092-8
pubmed: 18591282
N Engl J Med. 2015 Oct 8;373(15):1445-56
pubmed: 26444731
Clin Infect Dis. 2018 May 17;66(11):1678-1686
pubmed: 29438475
Mycoses. 2011 Jul;54(4):279-310
pubmed: 21672038
Int J Infect Dis. 2020 Apr;93:15-21
pubmed: 31982622
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37
pubmed: 23137135
J Antimicrob Chemother. 2017 Apr 1;72(4):1103-1108
pubmed: 28364558
Intensive Care Med. 2017 Nov;43(11):1613-1625
pubmed: 28374097
J Antimicrob Chemother. 2017 Jun 1;72(6):1784-1793
pubmed: 28333259
Clin Infect Dis. 2013 Jun;56(12):1724-32
pubmed: 23487382
Clin Microbiol Infect. 2014 Apr;20(4):O245-54
pubmed: 24125548
Intensive Care Med. 2017 Sep;43(9):1225-1238
pubmed: 28255613
Intensive Care Med. 2017 May;43(5):652-662
pubmed: 28321466
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S79-S94
pubmed: 30895218
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:53-67
pubmed: 23137137
PLoS One. 2015 Mar 30;10(3):e0120452
pubmed: 25822249
Clin Microbiol Infect. 2016 Aug;22(8):733.e1-8
pubmed: 27189197
N Engl J Med. 2007 Jun 14;356(24):2472-82
pubmed: 17568028
JAMA. 2016 Oct 18;316(15):1555-1564
pubmed: 27706483
Clin Infect Dis. 2016 Feb 15;62(4):409-17
pubmed: 26810419
Mycopathologia. 2020 Aug;185(4):685-690
pubmed: 32524348
Haematologica. 2017 Mar;102(3):433-444
pubmed: 28011902
Front Cell Infect Microbiol. 2019 Oct 11;9:352
pubmed: 31681629
Antimicrob Agents Chemother. 2011 Feb;55(2):532-8
pubmed: 21078946
Nat Rev Dis Primers. 2018 May 11;4:18026
pubmed: 29749387
Cochrane Database Syst Rev. 2016 Jul 11;7:CD011195
pubmed: 27398809
Clin Microbiol Infect. 2019 Oct;25(10):1200-1212
pubmed: 31039444
PLoS Pathog. 2017 May 18;13(5):e1006290
pubmed: 28542486
J Fungi (Basel). 2020 Aug 18;6(3):
pubmed: 32824785
Clin Infect Dis. 2012 Nov 15;55(10):1352-61
pubmed: 22893576
J Infect Dis. 2017 Aug 15;216(suppl_3):S484-S492
pubmed: 28911040
Ann Hematol. 2014 Jan;93(1):13-32
pubmed: 24026426
Emerg Infect Dis. 2014 Nov;20(11):1833-40
pubmed: 25340258
J Clin Microbiol. 2018 Mar 26;56(4):
pubmed: 29212705
BMC Infect Dis. 2017 Dec 6;17(1):753
pubmed: 29212442
J Infect. 2017 Apr;74(4):408-417
pubmed: 28104387
Intensive Care Med. 2014 Sep;40(9):1303-12
pubmed: 25097069
Int J Antimicrob Agents. 2009 Sep;34(3):205-9
pubmed: 19409759
Can J Infect Dis Med Microbiol. 2010 Winter;21(4):e122-50
pubmed: 22132006

Auteurs

Stéphane Bretagne (S)

Institut Pasteur, CNRS, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France.
Laboratoire de Parasitologie-Mycologie, Hôpital Saint Louis, AP-HP, Paris, France.
Université de Paris, Paris, France.

Marie Desnos-Ollivier (M)

Institut Pasteur, CNRS, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France.

Karine Sitbon (K)

Institut Pasteur, CNRS, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France.

Olivier Lortholary (O)

Institut Pasteur, CNRS, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France.
Université de Paris, Paris, France.
Service des Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Hôpital Necker-Enfants Malades, APHP, IHU Imagine, Paris, France.

Didier Che (D)

Santé publique France, Saint Maurice, France.

Françoise Dromer (F)

Institut Pasteur, CNRS, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France.

Classifications MeSH